Finance

Beta
Lists
RIGL:NASDAQ
Rigel Pharmaceuticals Inc
$29.93
-1.06%
(-0.32) 1D
$30.14
+0.70% (+0.21)
After hours
Closed: Jun 5, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RIGL...
Open
$30.33
High
$30.69
Low
$29.74
Mkt. cap
553.77M
Avg. vol.
402.13K
Volume
498.36K
P/E ratio
1.62
52-wk high
$52.06
52-wk low
$18.14
EPS
$18.43
Beta
1.20
Shares outstanding
18.50M
No. of employees
173
Open
$30.33
High
$30.69
Low
$29.74
Mkt. cap
553.77M
Avg. vol.
402.13K
Volume
498.36K
P/E ratio
1.62
52-wk high
$52.06
52-wk low
$18.14
EPS
$18.43
Beta
1.20
Shares outstanding
18.50M
No. of employees
173
Analyst outlook
Analyst Ratings
Based on 3 analysts giving stock ratings to RIGL in the past 3 months
Buy
Buy
2
Hold
1
Sell
0
12 month forecast
Based on 3 Wall Street analysts offering 12 month price targets for RIGL in the last 3 months.
Highest
Current $29.93
$81.00 (+170.63%)
Average
$59.33 (+98.23%)
Lowest
$40.00 (+33.65%)
News stories
From sources across the web
About Rigel Pharmaceuticals Inc
CEO-
Employees173
Founded1996
HeadquartersSouth San Francisco, California, United States
SectorBiotechnology
Websiterigel.com
Last report
May 5, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
$0.44 / $1.02
-56.99%miss
Revenue / Est. (USD)
58.82M / 62.92M
-6.52%miss
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
101.68M
69.46M
69.80M
58.82M
Cost of goods sold
11.32M
12.11M
16.64M
16.28M
Cost of revenue
11.32M
12.11M
16.64M
16.28M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
29.26M
28.94M
29.99M
30.65M
Operating expense
29.26M
28.94M
29.99M
30.65M
Total operating expenses
40.58M
41.04M
46.63M
46.93M
Operating income
61.10M
28.42M
23.17M
11.88M
Other non operating income
-
-
-
-
EBT including unusual items
59.98M
27.62M
22.71M
11.66M
EBT excluding unusual items
59.98M
27.62M
22.71M
11.66M
Income tax expense
369.00K
-280.00K
-245.35M
3.00M
Effective tax rate
0.62%
-1.01%
-1,080.18%
25.76%
Other operating expenses
-
-
-
-
Net income
59.61M
27.90M
268.06M
8.65M
Net profit margin
58.63%
40.17%
384.04%
14.71%
Earnings per share
3.28
1.46
1.12
0.44
Interest and investment income
753.00K
1.09M
1.24M
1.20M
Interest expense
-1.87M
-1.89M
-1.70M
-1.43M
Net interest expenses
-1.12M
-800.00K
-456.00K
-228.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
61.71M
29.02M
23.77M
12.48M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer